Mohr P - Search Results

1

Comparative evaluation of three FDA-approved HIV Ag/Ab combination tests using a genetically diverse HIV panel and diagnostic specimens.

Qiu X, Sokoll L, Yip P, Elliott DJ, Dua R, Mohr P, Wang XY, Spencer M, Swanson P, Dawson GJ, Hackett J Jr. Qiu X, et al. Among authors: mohr p. J Clin Virol. 2017 Jul;92:62-68. doi: 10.1016/j.jcv.2017.05.005. Epub 2017 May 13. J Clin Virol. 2017. PMID: 28535437 Free article.

2

Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men.

Sokoll LJ, Mangold LA, Partin AW, Epstein JI, Bruzek DJ, Dunn W, Mohr P, Wallerson G, Chan DW. Sokoll LJ, et al. Among authors: mohr p. Urology. 2002 Oct;60(4 Suppl 1):18-23. doi: 10.1016/s0090-4295(02)01692-8. Urology. 2002. PMID: 12384158

3

Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen.

Sokoll LJ, Bruzek DJ, Dua R, Dunn W, Mohr P, Wallerson G, Eisenberger M, Partin AW, Chan DW. Sokoll LJ, et al. Among authors: mohr p. Urology. 2002 Oct;60(4 Suppl 1):24-30. doi: 10.1016/s0090-4295(02)01723-5. Urology. 2002. PMID: 12384159

4

Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis.

Sokoll LJ, Chan DW, Mikolajczyk SD, Rittenhouse HG, Evans CL, Linton HJ, Mangold LA, Mohr P, Bartsch G, Klocker H, Horninger W, Partin AW. Sokoll LJ, et al. Among authors: mohr p. Urology. 2003 Feb;61(2):274-6. doi: 10.1016/s0090-4295(02)02398-1. Urology. 2003. PMID: 12597929

5

Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.

Khan MA, Sokoll LJ, Chan DW, Mangold LA, Mohr P, Mikolajczyk SD, Linton HJ, Evans CL, Rittenhouse HG, Partin AW. Khan MA, et al. Among authors: mohr p. Urology. 2004 Dec;64(6):1160-4. doi: 10.1016/j.urology.2004.06.033. Urology. 2004. PMID: 15596190

6

Serum leptin and pathological findings at the time of radical prostatectomy.

Freedland SJ, Sokoll LJ, Mangold LA, Bruzek DJ, Mohr P, Yiu SK, Epstein JI, Partin AW. Freedland SJ, et al. Among authors: mohr p. J Urol. 2005 Mar;173(3):773-6. doi: 10.1097/01.ju.0000152619.96795.b2. J Urol. 2005. PMID: 15711267

7

Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy.

Freedland SJ, Sokoll LJ, Platz EA, Mangold LA, Bruzek DJ, Mohr P, Yiu SK, Partin AW. Freedland SJ, et al. Among authors: mohr p. J Urol. 2005 Oct;174(4 Pt 1):1266-70. doi: 10.1097/01.ju.0000173093.89897.97. J Urol. 2005. PMID: 16145390

8

High "phi"ve.

Sokoll LJ, Mangold L, Mohr P, Dua R, Partin AW. Sokoll LJ, et al. Among authors: mohr p. J Appl Lab Med. 2018 Sep 1;3(2):333-335. doi: 10.1373/jalm.2018.027482. J Appl Lab Med. 2018. PMID: 33636944 No abstract available.

9

Prevalence of Detectable Biotin in Five US Emergency Department Patient Cohorts.

Gunsolus IL, Matias M, Prostko J, Mohr P, Sokoll LJ. Gunsolus IL, et al. Among authors: mohr p. Clin Biochem. 2021 Jul;93:26-32. doi: 10.1016/j.clinbiochem.2021.03.009. Epub 2021 Mar 24. Clin Biochem. 2021. PMID: 33771568

10

A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer.

Song J, Ma S, Sokoll LJ, Eguez RV, Höti N, Zhang H, Mohr P, Dua R, Patil D, May KD, Williams S, Arnold R, Sanda MG, Chan DW, Zhang Z. Song J, et al. Among authors: mohr p. Theranostics. 2021 Apr 15;11(13):6214-6224. doi: 10.7150/thno.55676. eCollection 2021. Theranostics. 2021. PMID: 33995654 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

591 results

Search Page

Filters